Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. on January 23, 2023. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Boston, MA. The filing primarily addresses amendments to a material agreement with 3i, LP regarding Series A Convertible Preferred Stock and discloses the company's proposed annual budget for the 2023 calendar year.
Key Financial Metrics and Liquidity
The filing does not report historical revenue, profit, or cash flow figures for a completed period. Instead, it outlines the proposed 2023 annual budget, which represents projected total annual expenditures:
- Milestone Payments: Approximately $4,924,000 (related to license agreements and patents).
- Development Costs: Approximately $10,496,000 (including clinical trial costs).
- General and Operating Expenses: Approximately $6,262,000.
- Total Projected Expenditures: Approximately $21,682,000.
The company intends to finance this budget through the raising of capital. The filing explicitly states that no assurance can be given that the company will be able to raise a sufficient amount of capital to finance its 2023 budget.
Material Changes and Agreements
Amendment to Letter Agreement with 3i, LP:
- On December 9, 2022, the Company and 3i entered into a Letter Agreement modifying the Conversion Price of Series A Preferred Stock to the lower of the Closing Sale Price on the trading day preceding the Conversion Date or the average Closing Sale Price for the five trading days preceding the Conversion Date.
- On January 23, 2023, the parties amended this agreement to extend the term of this modified Conversion Price until terminated by either the Company or 3i.
- 3i is also a holder of a secured promissory note issued by the Company under agreements dated November 22, 2022.
Outlook, Risks, and Management Commentary
Management has disclosed the 2023 budget as forward-looking information. The company notes that actual expenses and payments will differ from month to month due to the timing of development costs and contractual milestone payments. The filing references the "Risk Factors" section in the Form 10-K for the year ended December 31, 2022, for a comprehensive list of risks and uncertainties that could cause actual results to differ materially from expectations.
Key Facts for Investor Verification
- Verify the company's ability to raise the approximately $21.7 million required to fund its 2023 operations and development plans.
- Monitor the status of the Series A Convertible Preferred Stock held by 3i, LP, specifically regarding the indefinite extension of the modified Conversion Price.
- Review the Form 10-K for the year ended December 31, 2022, for detailed risk factors and historical financial context not included in this 8-K.
- Track the timing of milestone payments and clinical trial costs, as these will drive monthly cash burn rates.